Invesco Ltd. Has $951,000 Holdings in CRISPR Therapeutics AG $CRSP

Invesco Ltd. trimmed its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 17.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,957 shares of the company’s stock after selling 5,833 shares during the quarter. Invesco Ltd.’s holdings in CRISPR Therapeutics were worth $951,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Benjamin Edwards Inc. lifted its holdings in shares of CRISPR Therapeutics by 13.0% during the 1st quarter. Benjamin Edwards Inc. now owns 50,915 shares of the company’s stock valued at $1,733,000 after buying an additional 5,853 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in shares of CRISPR Therapeutics by 9.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,725 shares of the company’s stock valued at $195,000 after buying an additional 473 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of CRISPR Therapeutics by 1.9% during the 1st quarter. Vanguard Group Inc. now owns 1,769,709 shares of the company’s stock valued at $60,223,000 after buying an additional 33,711 shares during the last quarter. Costello Asset Management INC acquired a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at about $27,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its holdings in shares of CRISPR Therapeutics by 79.8% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 65,195 shares of the company’s stock valued at $2,219,000 after buying an additional 28,931 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CRSP. Piper Sandler reiterated an “overweight” rating and set a $105.00 price target on shares of CRISPR Therapeutics in a report on Friday, June 27th. Bank of America lowered their price objective on CRISPR Therapeutics from $79.00 to $78.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. JMP Securities reissued a “market outperform” rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Friday, June 27th. Needham & Company LLC restated a “buy” rating and issued a $81.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, July 8th. Finally, Barclays boosted their target price on CRISPR Therapeutics from $42.00 to $56.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus target price of $71.60.

CRISPR Therapeutics Trading Up 1.6%

Shares of CRSP stock opened at $52.66 on Wednesday. The stock has a 50 day moving average of $55.98 and a two-hundred day moving average of $45.42. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $71.13. The company has a market capitalization of $4.79 billion, a P/E ratio of -9.70 and a beta of 1.81.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.18. The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $6.44 million. CRISPR Therapeutics had a negative return on equity of 20.05% and a negative net margin of 1,229.43%.CRISPR Therapeutics’s quarterly revenue was up 72.5% on a year-over-year basis. During the same period in the previous year, the business posted ($1.49) earnings per share. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Simeon George acquired 989,812 shares of the stock in a transaction dated Wednesday, July 16th. The shares were acquired at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the transaction, the director owned 1,730,179 shares in the company, valued at approximately $90,021,213.37. This trade represents a 133.69% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.10% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.